Avastin Labeling Will Reflect New Data On Thromboembolic Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech's "Dear Doctor" letter cites evidence of an "increased risk of serious arterial thromboembolic events" related to use of the oncologic. A revised package insert containing more detailed information on arterial thromboembolic events across five studies is in development, the company says.